We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merrimack Announces Positive Data on Oncology Candidate
Read MoreHide Full Article
Merrimack Pharmaceuticals, Inc. (MACK - Free Report) announced results from the final analysis of the phase I study on pipeline candidate, MM-151, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago.
MM-151 is a novel investigational oligoclonal epidermal growth factor receptor (EGFR) inhibitor in patients with refractory solid tumors.
Data from the phase I study showed positive clinical activity across multiple solid tumor types in a heavily pretreated patient population. While 21% of evaluable patients in the metastatic colorectal cancer (CRC) cohort achieved an objective response, 54% of patients showed a decrease in tumor size. The CRC cohort demonstrated a median progression-free survival (PFS) of four months. The candidate also showed positive clinical activity in both the EGFR-treatment-refractory and EGFR-treatment-naïve populations.
As per the American Cancer Society, CRC is the third-most common type of cancer and the second leading cause of cancer-related death in the U.S., with an estimated 144,000 new cases to be diagnosed in 2016.
Meanwhile, MM-151 is being evaluated in two other phase I studies – one in combination with the Onivyde (irinotecan liposome injection) regimen for metastatic CRC, and a first-of-its-kind, multi-arm basket study on a combination of the candidate with three other novel agents. Both these studies were initiated this May.
Merrimack has gained FDA approval for its first product, Onivyde, in Oct 2015. Onivyde is approved for use, in combination with fluorouracil (5-FU) and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following Gemzar (gemcitabine)-based therapy.
Also, this makes Merrimack heavily dependent on Onivyde for growth. As a result, the company needs to work extensively on its pipeline to reduce dependence on a single product.
Merrimack Pharma carries a Zacks Rank #2 (Buy). Other favorably placed stocks in the health care sector include Pfizer Inc. (PFE - Free Report) , Johnson & Johnson (JNJ - Free Report) and Abbott Laboratories (ABT - Free Report) . While Pfizer sports a Zacks Rank #1 (Strong Buy), Johnson & Johnson and Abbott Labs carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merrimack Announces Positive Data on Oncology Candidate
Merrimack Pharmaceuticals, Inc. (MACK - Free Report) announced results from the final analysis of the phase I study on pipeline candidate, MM-151, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago.
MM-151 is a novel investigational oligoclonal epidermal growth factor receptor (EGFR) inhibitor in patients with refractory solid tumors.
Data from the phase I study showed positive clinical activity across multiple solid tumor types in a heavily pretreated patient population. While 21% of evaluable patients in the metastatic colorectal cancer (CRC) cohort achieved an objective response, 54% of patients showed a decrease in tumor size. The CRC cohort demonstrated a median progression-free survival (PFS) of four months. The candidate also showed positive clinical activity in both the EGFR-treatment-refractory and EGFR-treatment-naïve populations.
As per the American Cancer Society, CRC is the third-most common type of cancer and the second leading cause of cancer-related death in the U.S., with an estimated 144,000 new cases to be diagnosed in 2016.
Meanwhile, MM-151 is being evaluated in two other phase I studies – one in combination with the Onivyde (irinotecan liposome injection) regimen for metastatic CRC, and a first-of-its-kind, multi-arm basket study on a combination of the candidate with three other novel agents. Both these studies were initiated this May.
Merrimack has gained FDA approval for its first product, Onivyde, in Oct 2015. Onivyde is approved for use, in combination with fluorouracil (5-FU) and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following Gemzar (gemcitabine)-based therapy.
Also, this makes Merrimack heavily dependent on Onivyde for growth. As a result, the company needs to work extensively on its pipeline to reduce dependence on a single product.
Merrimack Pharma carries a Zacks Rank #2 (Buy). Other favorably placed stocks in the health care sector include Pfizer Inc. (PFE - Free Report) , Johnson & Johnson (JNJ - Free Report) and Abbott Laboratories (ABT - Free Report) . While Pfizer sports a Zacks Rank #1 (Strong Buy), Johnson & Johnson and Abbott Labs carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>